TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $28,421,085 | +133.7% | 1,263,721 | +118.5% | 1.82% | +151.8% |
Q4 2022 | $12,160,976 | +25.0% | 578,268 | +46.5% | 0.72% | +27.6% |
Q3 2022 | $9,725,000 | +88.8% | 394,678 | +85.6% | 0.57% | +31.9% |
Q2 2022 | $5,151,000 | -69.6% | 212,593 | -67.7% | 0.43% | -66.7% |
Q1 2022 | $16,963,000 | -47.5% | 658,249 | -36.8% | 1.29% | -31.8% |
Q4 2021 | $32,308,000 | +204.7% | 1,040,858 | +138.0% | 1.89% | +200.5% |
Q3 2021 | $10,604,000 | – | 437,280 | – | 0.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |